Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients. Data from the danuglipron clinical development program will be presented at a scientific forum or submitted for publication in a peer-reviewed journal in the future
Store your container safely Keep your disposal container upright and out of reach of children and pets
Selective GHS-R1a activation enables researchers to isolate specific receptor-mediated effects
People with those cancers who took liraglutide, pramlintide, dulaglutide, tirzepatide, lixisenatide, or semaglutide were 38% to 50% less likely to see the disease spread than people who took drugs from a different class of diabetes medicines known as gliptins
US$ 23.54
US$ 21.36
US$ 27.71
US$ 24.43
US$ 26.28
US$ 25.73
